These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 394864)
21. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
22. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. Tancini G; Bonadonna G; Valagussa P; Marchini S; Veronesi U J Clin Oncol; 1983 Jan; 1(1):2-10. PubMed ID: 6366125 [TBL] [Abstract][Full Text] [Related]
23. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Brincker H; Mouridsen HT; Andersen KW Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278 [TBL] [Abstract][Full Text] [Related]
25. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Zambetti M; Veronesi U Breast Cancer Res Treat; 1985; 5(2):95-115. PubMed ID: 3839424 [TBL] [Abstract][Full Text] [Related]
26. Are surgical adjuvant trials altering the course of breast cancer? Bonadonna G; Valagussa P; Rossi A; Zucali R; Tancini G; Bajetta E; Brambilla C; De Lena M; Di Fronzo G; Banfi A; Rilke F; Veronesi U Semin Oncol; 1978 Dec; 5(4):450-64. PubMed ID: 366757 [No Abstract] [Full Text] [Related]
27. Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes. Valagussa P; Tess JD; Rossi A; Tancini G; Banfi A; Bonadonna G Breast Cancer Res Treat; 1981; 1(4):349-56. PubMed ID: 6897368 [TBL] [Abstract][Full Text] [Related]
28. Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Rossi A; Bonadonna G; Valagussa P; Veronesi U Br Med J (Clin Res Ed); 1981 May; 282(6274):1427-31. PubMed ID: 6784849 [TBL] [Abstract][Full Text] [Related]
29. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada. Klaassen DJ; Boyes DA; Gerulath A; Levitt M; Miller AB; Pearson JG Cancer Treat Rep; 1979 Feb; 63(2):289-95. PubMed ID: 376135 [No Abstract] [Full Text] [Related]
30. Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Ahmann DL; O'Fallon J; O'Connell MJ; Bisel HF; Hahn RG; Frytak S; Edmonson JH; Rubin J; Ingle JN; Kvols LK Cancer Clin Trials; 1978; 1(3):219-26. PubMed ID: 391427 [TBL] [Abstract][Full Text] [Related]
36. Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Groupe B. Falkson G; Falkson HC; Glidewell O; Weinberg V; Leone L; Holland JF Cancer; 1979 Jun; 43(6):2215-22. PubMed ID: 378348 [TBL] [Abstract][Full Text] [Related]
37. Improved survival with combined modality treatment for stage IV breast cancer. Nervi C; Arcangeli G; Concolino F; Cortese M Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1317-21. PubMed ID: 393672 [No Abstract] [Full Text] [Related]
38. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Wu S; Li Q; Zhu Y; Sun J; Li F; Lin H; Guan X; He Z Cancer Biother Radiopharm; 2013 Dec; 28(10):697-702. PubMed ID: 23806020 [TBL] [Abstract][Full Text] [Related]
39. Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. Gwak G; Park K; Shin E; Han S; Kim JY; Kim H; Kim YD; Kim HJ; Kim KW; Bae BN; Yang KH; Cho H; Park SJ J Breast Cancer; 2011 Sep; 14(3):223-8. PubMed ID: 22031805 [TBL] [Abstract][Full Text] [Related]
40. Current status and indications for adjuvant therapy in breast cancer. Senn HJ Cancer Chemother Pharmacol; 1982; 8(2):139-50. PubMed ID: 7049436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]